

Table of Contents

Number	Title
1	Table 00: Comments
2	Table 01: Study population and enrolment information
3	Table 02: Patients by region, country, and cohort
4	Table 03 : Demographic Characteristics
5	Table 04 : Care setting , Type of AF and Insurance
6	Table 05 : Vital signs and life style
7	Table 06 : Clinical History
8	Table 07 : Treatment for stroke prophylaxis
9	Table 08: Treatment
10	Table 09 : Risk scores
11	Table 10: Treatment at baseline by CHA2DS2-VASc score
12	Table 11: Treatment at baseline by HAS-BLED score
13	Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4
14	Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
15	Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
16	Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
17	Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
18	Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
19	Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4

Table 00: Comments

- 1 The data was extracted from the GARFIELD-AF registry database on 28 JUL 2016
- 2 The data includes retrospective patients in cohort 1 and prospective patients in cohort 1, 2, 3, 4 and 5
- 3 The variable 'Congestive heart failure' was split into 'History of CHF' and 'Current CHF' in cohorts 3, 4 and 5. History of and/or current CHF were used to identify CHF in cohort 3, 4 and 5 patients (Table 6)
- 4 The variable 'Coronary artery disease' was split into 'History of CAD' and 'Current CAD' in cohorts 3, 4 and 5. History of and/or current CAD were used to identify CAD in cohort 3, 4 and 5 patients (Table 6)
- 5 The variable 'Other thromboembolism' is not recorded for patients in cohort 3, 4 and 5
- 6 The option 'None' was added in the CRF for the 'Chronic renal disease' field in cohort 3, 4 and 5. The percentages for the variable 'Moderate to severe CKD' are estimated assuming that patients with 'unknown' stage of CKD are without 'Moderate to severe CKD' (Table 6)
- 7 Table 7 describes the baseline treatment for stroke prophylaxis. For each treatment group identifier options are mutually exclusive. The option 'unknown' includes combination of treatments
- 8 Table 8 shows the baseline treatment for stroke prophylaxis with non mutually exclusive groups
- 9 Table 12 shows INR values and TTR for patients treated with VKA±AP at baseline. INR readings during the first year of follow-up were included in the analysis. Values less than 0.8 or greater than 20 were removed since these values may not be plausible. Patients on VKA±AP at enrolment but with fewer than three readings during the follow-up were excluded from the analysis. Patient-level TTR was estimated by linear interpolation according to Rosendaal et al (1993), using 2.0-3.0 as the target INR range. TTR was estimated using INR readings until discontinuation or interruption of VKA or the end of follow-up. In addition, TTR was estimated between two consecutive INR readings only if the interval did not exceed 90 days.
- 10 Tables 13 and 14 describe events during the first year of follow-up for patients in cohorts 1-4. Only the first occurrence of each event was taken into account.
- 11 Table 13 Congestive heart failure during the follow-up includes new congestive heart failure or worsening of pre-existing congestive heart failure.

**Table 01: Study population and enrolment information
Full Analysis Dataset : CHINA**

Number of prospective patients (C1+C2+C3+C4+C5)	2460
Number of enrolling sites	29
Number of enrolling countries	1
Enrolment period	23JUN2010 - 26JUL2016
Duration of enrolment (months)	73.1

**Table 02: Patients by region, country, and cohort
Full Analysis Dataset : CHINA**

Region	Country	Cohort 1 Retrospective patients (N=305)	Cohort 1 Prospective patients (N=495)	Cohort 2 (N=444)	Cohort 3 (N=504)	Cohort 4 (N=530)	Cohort 5 (N=487)	Total Prospective patients Cohorts 1 to 5 (N=2460)	Total Prospective patients Cohorts 1 to 4 (N=1973)
Asia	China	305	495	444	504	530	487	2460	1973

**Table 03 : Demographic Characteristics
Full Analysis Dataset : CHINA**

Variable	Statistics	Cohort 1 Retrospective patients (N=305) (n %)	Cohort 1 Prospective patients (N=495) (n %)	Cohort 2 (N=444) (n %)	Cohort 3 (N=504) (n %)	Cohort 4 (N=530) (n %)	Cohort 5 (N=487) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2460)	Total Prospective patients Cohorts 1 to 4 (N=1973)
Sex, n(%)	n (missing)	305 (0)	495 (0)	444 (0)	504 (0)	530 (0)	487 (0)	2460 (0)	1973 (0)
	Male	190 (62.3)	294 (59.4)	260 (58.6)	277 (55.0)	286 (54.0)	294 (60.4)	1411 (57.4)	1117 (56.6)
	Female	115 (37.7)	201 (40.6)	184 (41.4)	227 (45.0)	244 (46.0)	193 (39.6)	1049 (42.6)	856 (43.4)
Age at Diagnosis (Years)	n (missing)	305 (0)	495 (0)	444 (0)	504 (0)	530 (0)	487 (0)	2460 (0)	1973 (0)
	Mean (SD)	65.5 (11.2)	66.6 (11.7)	67.2 (10.9)	67.2 (11.3)	66.5 (11.8)	67.1 (10.7)	66.9 (11.3)	66.9 (11.4)
	Median (IQR)	67.0 (58.0 to 74.0)	69.0 (58.0 to 75.0)	69.0 (60.0 to 75.0)	69.0 (60.0 to 76.0)	68.0 (59.0 to 75.0)	68.0 (60.0 to 75.0)	69.0 (59.0 to 75.0)	69.0 (59.0 to 75.0)
	Min to Max	32 to 99	20 to 99	34 to 90	28 to 91	26 to 93	34 to 89	20 to 99	20 to 99
Age Group, n(%)	n (missing)	305 (0)	495 (0)	444 (0)	504 (0)	530 (0)	487 (0)	2460 (0)	1973 (0)
	<65	118 (38.7)	193 (39.0)	168 (37.8)	194 (38.5)	205 (38.7)	186 (38.2)	946 (38.5)	760 (38.5)
	65-74	117 (38.4)	167 (33.7)	150 (33.8)	154 (30.6)	181 (34.2)	170 (34.9)	822 (33.4)	652 (33.0)
	>=75	70 (23.0)	135 (27.3)	126 (28.4)	156 (31.0)	144 (27.2)	131 (26.9)	692 (28.1)	561 (28.4)
Time since AF Diagnosis (Weeks)	n (missing)	305 (0)	436 (59)	365 (79)	446 (58)	481 (49)	388 (99)	2116 (344)	1728 (245)
	Mean (SD)	61.33 (24.34)	1.89 (1.68)	1.79 (1.61)	1.91 (1.61)	1.94 (1.79)	1.81 (1.56)	1.87 (1.66)	1.89 (1.68)
	Median (IQR)	57.10 (39.80 to 83.20)	1.30 (0.50 to 2.80)	1.20 (0.50 to 2.70)	1.40 (0.70 to 3.00)	1.20 (0.50 to 3.10)	1.20 (0.50 to 2.70)	1.40 (0.50 to 2.80)	1.40 (0.50 to 3.00)
	Min to Max	26.1 to 104.2	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 14.2	0.1 to 6.0	0.1 to 14.2	0.1 to 14.2
Race, n(%)	n (missing)	305 (0)	495 (0)	444 (0)	504 (0)	530 (0)	487 (0)	2460 (0)	1973 (0)
	Asian (Not Chinese)	3 (1.0)	4 (0.8)	2 (0.5)	-	-	1 (0.2)	7 (0.3)	6 (0.3)
	Chinese	302 (99.0)	491 (99.2)	442 (99.5)	504 (100.0)	529 (99.8)	486 (99.8)	2452 (99.7)	1966 (99.6)
	Mixed/Other	-	-	-	-	1 (0.2)	-	1 (0.0)	1 (0.1)

**Table 03 : Demographic Characteristics
Full Analysis Dataset : CHINA**

Variable	Statistics	Cohort 1 Retrospective patients (N=305) (n %)	Cohort 1 Prospective patients (N=495) (n %)	Cohort 2 (N=444) (n %)	Cohort 3 (N=504) (n %)	Cohort 4 (N=530) (n %)	Cohort 5 (N=487) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2460)	Total Prospective patients Cohorts 1 to 4 (N=1973)
Region, n(%)	n (missing)	305 (0)	495 (0)	444 (0)	504 (0)	530 (0)	487 (0)	2460 (0)	1973 (0)
	Asia	305 (100.0)	495 (100.0)	444 (100.0)	504 (100.0)	530 (100.0)	487 (100.0)	2460 (100.0)	1973 (100.0)

**Table 04 : Care setting , Type of AF and Insurance
Full Analysis Dataset : CHINA**

Variable	Statistics	Cohort 1 Retrospective patients (N=305) (n %)	Cohort 1 Prospective patients (N=495) (n %)	Cohort 2 (N=444) (n %)	Cohort 3 (N=504) (n %)	Cohort 4 (N=530) (n %)	Cohort 5 (N=487) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2460)	Total Prospective patients Cohorts 1 to 4 (N=1973)
Care Setting Speciality at Diagnosis, n(%)	n (missing)	305 (0)	495 (0)	444 (0)	504 (0)	530 (0)	487 (0)	2460 (0)	1973 (0)
	Internal Medicine	61 (20.0)	93 (18.8)	76 (17.1)	35 (6.9)	40 (7.5)	33 (6.8)	277 (11.3)	244 (12.4)
	Cardiology	239 (78.4)	395 (79.8)	361 (81.3)	455 (90.3)	477 (90.0)	449 (92.2)	2137 (86.9)	1688 (85.6)
	Neurology	1 (0.3)	5 (1.0)	2 (0.5)	2 (0.4)	2 (0.4)	-	11 (0.4)	11 (0.6)
	Geriatrics	-	1 (0.2)	4 (0.9)	1 (0.2)	1 (0.2)	-	7 (0.3)	7 (0.4)
	Primary Care/General Practice	4 (1.3)	1 (0.2)	1 (0.2)	11 (2.2)	10 (1.9)	5 (1.0)	28 (1.1)	23 (1.2)
Care Setting Location at Diagnosis, n(%)	n (missing)	304 (0)	495 (0)	444 (0)	504 (0)	530 (0)	487 (0)	2460 (0)	1973 (0)
	Hospital	294 (96.7)	483 (97.6)	431 (97.1)	492 (97.6)	515 (97.2)	483 (99.2)	2404 (97.7)	1921 (97.4)
	Office	5 (1.6)	3 (0.6)	3 (0.7)	3 (0.6)	2 (0.4)	-	11 (0.4)	11 (0.6)
	Anticoagulation clinic/thrombosi s centre	-	-	2 (0.5)	-	-	1 (0.2)	3 (0.1)	2 (0.1)
	Emergency room	5 (1.6)	9 (1.8)	8 (1.8)	9 (1.8)	13 (2.5)	3 (0.6)	42 (1.7)	39 (2.0)
	Unknown	1	-	-	-	-	-	-	-
Type of AF Diagnosed, n(%)	n (missing)	305 (0)	495 (0)	444 (0)	504 (0)	530 (0)	487 (0)	2460 (0)	1973 (0)
	Permanent	106 (34.8)	46 (9.3)	24 (5.4)	77 (15.3)	53 (10.0)	21 (4.3)	221 (9.0)	200 (10.1)
	Persistent	73 (23.9)	86 (17.4)	55 (12.4)	33 (6.5)	21 (4.0)	33 (6.8)	228 (9.3)	195 (9.9)
	Paroxysmal	121 (39.7)	113 (22.8)	127 (28.6)	144 (28.6)	102 (19.2)	113 (23.2)	599 (24.3)	486 (24.6)
	New	5 (1.6)	250 (50.5)	238 (53.6)	250 (49.6)	354 (66.8)	320 (65.7)	1412 (57.4)	1092 (55.3)

**Table 04 : Care setting , Type of AF and Insurance
Full Analysis Dataset : CHINA**

Variable	Statistics	Cohort 1 Retrospective patients (N=305) (n %)	Cohort 1 Prospective patients (N=495) (n %)	Cohort 2 (N=444) (n %)	Cohort 3 (N=504) (n %)	Cohort 4 (N=530) (n %)	Cohort 5 (N=487) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2460)	Total Prospective patients Cohorts 1 to 4 (N=1973)
Treatment Costs, n(%)	n (missing)	-	-	343 (0)	407 (0)	405 (0)	381 (0)	1536 (0)	1155 (0)
	Public insurance	-	-	294 (85.7)	289 (71.0)	233 (57.5)	280 (73.5)	1096 (71.4)	816 (70.6)
	Private (insurance)	-	-	5 (1.5)	2 (0.5)	1 (0.2)	3 (0.8)	11 (0.7)	8 (0.7)
	Private (out of pocke	-	-	30 (8.7)	53 (13.0)	53 (13.1)	18 (4.7)	154 (10.0)	136 (11.8)
	Combination	-	-	14 (4.1)	63 (15.5)	118 (29.1)	80 (21.0)	275 (17.9)	195 (16.9)
	Unknown	305	495	101	97	125	106	924	818
Treatment Sector, n(%)	n (missing)	-	6 (0)	398 (0)	481 (0)	520 (0)	480 (0)	1885 (0)	1405 (0)
	In the public sector	-	6 (100.0)	392 (98.5)	481 (100.0)	511 (98.3)	479 (99.8)	1869 (99.2)	1390 (98.9)
	In the private sector	-	-	6 (1.5)	-	9 (1.7)	1 (0.2)	16 (0.8)	15 (1.1)
	Unknown	305	489	46	23	10	7	575	568

**Table 05 : Vital signs and life style
Full Analysis Dataset : CHINA**

Variable	Statistics	Cohort 1 Retrospective patients (N=305) (n %)	Cohort 1 Prospective patients (N=495) (n %)	Cohort 2 (N=444) (n %)	Cohort 3 (N=504) (n %)	Cohort 4 (N=530) (n %)	Cohort 5 (N=487) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2460)	Total Prospective patients Cohorts 1 to 4 (N=1973)
Height (cm)	n (missing)	260 (45)	440 (55)	354 (90)	431 (73)	430 (100)	427 (60)	2082 (378)	1655 (318)
	Mean (SD)	166.2 (8.0)	165.6 (8.0)	166.0 (7.9)	165.8 (8.4)	164.9 (7.9)	165.9 (8.1)	165.6 (8.1)	165.5 (8.1)
	Median (IQR)	168.0 (160.0 to 172.0)	165.0 (160.0 to 172.0)	167.0 (160.0 to 172.0)	165.0 (160.0 to 172.0)	165.0 (160.0 to 170.0)	166.0 (160.0 to 172.0)	165.0 (160.0 to 172.0)	165.0 (160.0 to 172.0)
	Min to Max	145 to 183	145 to 190	143 to 184	146 to 185	145 to 187	145 to 187	143 to 190	143 to 190
Weight (kg)	n (missing)	260 (45)	440 (55)	354 (90)	431 (73)	430 (100)	427 (60)	2082 (378)	1655 (318)
	Mean (SD)	67.6 (11.5)	66.1 (12.3)	68.2 (12.1)	67.6 (12.8)	68.1 (12.4)	68.2 (12.1)	67.6 (12.4)	67.4 (12.4)
	Median (IQR)	68.0 (60.0 to 75.0)	65.0 (56.0 to 75.0)	68.0 (60.0 to 76.0)	68.0 (60.0 to 76.0)	68.0 (60.0 to 75.0)	67.0 (60.0 to 75.0)	67.0 (60.0 to 75.0)	67.0 (60.0 to 75.0)
	Min to Max	38 to 108	37 to 108	35 to 110	35 to 107	30 to 115	40 to 130	30 to 130	30 to 115
BMI (kg/m ²)	n (missing)	260 (45)	440 (55)	354 (90)	431 (73)	430 (100)	427 (60)	2082 (378)	1655 (318)
	Mean (SD)	24.4 (3.2)	24.1 (3.5)	24.7 (3.6)	24.5 (3.7)	25.0 (3.7)	24.7 (3.4)	24.6 (3.6)	24.6 (3.6)
	Median (IQR)	24.0 (22.0 to 26.0)	24.0 (22.0 to 26.0)	25.0 (22.0 to 27.0)	24.0 (22.0 to 27.0)	25.0 (23.0 to 27.0)	24.0 (22.0 to 27.0)	24.0 (22.0 to 27.0)	24.0 (22.0 to 27.0)
	Min to Max	16 to 37	15 to 39	14 to 36	16 to 35	12 to 44	15 to 39	12 to 44	12 to 44
BMI Category, n(%)	n (missing)	260 (45)	440 (55)	354 (90)	431 (73)	430 (100)	427 (60)	2082 (378)	1655 (318)
	<19	13 (5.0)	30 (6.8)	23 (6.5)	32 (7.4)	20 (4.7)	12 (2.8)	117 (5.6)	105 (6.3)
	19-<25	142 (54.6)	248 (56.4)	158 (44.6)	209 (48.5)	209 (48.6)	233 (54.6)	1057 (50.8)	824 (49.8)
	25-<30	91 (35.0)	139 (31.6)	152 (42.9)	159 (36.9)	168 (39.1)	149 (34.9)	767 (36.8)	618 (37.3)
	30-<40	14 (5.4)	23 (5.2)	21 (5.9)	31 (7.2)	32 (7.4)	33 (7.7)	140 (6.7)	107 (6.5)
	>=40	-	-	-	-	1 (0.2)	-	1 (0.0)	1 (0.1)
Pulse (bpm)	n (missing)	271 (34)	462 (33)	432 (12)	493 (11)	521 (9)	483 (4)	2391 (69)	1908 (65)
	Mean (SD)	84.8 (20.2)	88.2 (23.0)	84.8 (25.0)	83.2 (20.6)	83.3 (22.2)	85.9 (22.6)	85.0 (22.7)	84.8 (22.7)
	Median (IQR)	80.0 (70.0 to 95.0)	84.0 (72.0 to 98.0)	80.0 (68.0 to 95.5)	80.0 (70.0 to 94.0)	79.0 (68.0 to 95.0)	80.0 (70.0 to 98.0)	80.0 (70.0 to 96.0)	80.0 (70.0 to 96.0)
	Min to Max	48 to 160	43 to 180	46 to 182	40 to 165	37 to 175	44 to 210	37 to 210	37 to 182

**Table 05 : Vital signs and life style
Full Analysis Dataset : CHINA**

Variable	Statistics	Cohort 1 Retrospective patients (N=305) (n %)	Cohort 1 Prospective patients (N=495) (n %)	Cohort 2 (N=444) (n %)	Cohort 3 (N=504) (n %)	Cohort 4 (N=530) (n %)	Cohort 5 (N=487) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2460)	Total Prospective patients Cohorts 1 to 4 (N=1973)
Systolic BP (mm Hg)	n (missing)	274 (31)	459 (36)	432 (12)	498 (6)	524 (6)	484 (3)	2397 (63)	1913 (60)
	Mean (SD)	133.2 (18.6)	131.7 (18.9)	132.9 (19.7)	132.8 (20.8)	133.6 (18.9)	133.0 (19.8)	132.8 (19.6)	132.8 (19.6)
	Median (IQR)	130.0 (120.0 to 140.0)	130.0 (120.0 to 142.0)	130.0 (120.0 to 142.0)	130.0 (120.0 to 142.0)	130.0 (120.0 to 144.0)	130.0 (120.0 to 145.0)	130.0 (120.0 to 144.0)	130.0 (120.0 to 143.0)
	Min to Max	80 to 200	80 to 192	86 to 200	70 to 221	81 to 203	80 to 210	70 to 221	70 to 221
Diastolic BP (mm Hg)	n (missing)	274 (31)	459 (36)	432 (12)	498 (6)	524 (6)	484 (3)	2397 (63)	1913 (60)
	Mean (SD)	80.2 (11.0)	79.0 (12.1)	78.4 (12.1)	78.5 (14.0)	80.7 (13.1)	80.8 (13.5)	79.5 (13.1)	79.2 (12.9)
	Median (IQR)	80.0 (70.0 to 88.0)	80.0 (70.0 to 86.0)	80.0 (70.0 to 85.0)	80.0 (70.0 to 85.0)	80.0 (70.0 to 89.0)	80.0 (70.0 to 90.0)	80.0 (70.0 to 88.0)	80.0 (70.0 to 87.0)
	Min to Max	55 to 120	45 to 126	43 to 135	40 to 159	49 to 130	50 to 146	40 to 159	40 to 159
LVEF (%)	n (missing)	171 (134)	361 (134)	289 (155)	358 (146)	424 (106)	323 (164)	1755 (705)	1432 (541)
	Mean (SD)	58.6 (13.1)	58.3 (12.1)	59.2 (11.7)	58.2 (11.5)	58.1 (10.7)	57.5 (11.5)	58.3 (11.5)	58.4 (11.4)
	Median (IQR)	62.0 (52.0 to 68.0)	60.0 (52.0 to 67.0)	60.0 (53.0 to 67.0)	61.0 (54.0 to 66.0)	60.0 (54.0 to 65.0)	60.0 (52.0 to 66.0)	60.0 (53.0 to 66.0)	60.0 (53.0 to 66.0)
	Min to Max	16 to 85	21 to 84	17 to 82	18 to 87	19 to 80	23 to 80	17 to 87	17 to 87
LVEF Category, n (missing) n(%)	n (missing)	171 (134)	361 (134)	289 (155)	358 (146)	424 (106)	323 (164)	1755 (705)	1432 (541)
	<40%	22 (12.9)	29 (8.0)	17 (5.9)	27 (7.5)	25 (5.9)	35 (10.8)	133 (7.6)	98 (6.8)
	>=40%	149 (87.1)	332 (92.0)	272 (94.1)	331 (92.5)	399 (94.1)	288 (89.2)	1622 (92.4)	1334 (93.2)
History of Hypertension, n(%)	n (missing)	305 (0)	495 (0)	444 (0)	497 (0)	522 (0)	485 (0)	2443 (0)	1958 (0)
	No	81 (26.6)	155 (31.3)	116 (26.1)	137 (27.6)	134 (25.7)	154 (31.8)	696 (28.5)	542 (27.7)
	Yes	224 (73.4)	340 (68.7)	328 (73.9)	360 (72.4)	388 (74.3)	331 (68.2)	1747 (71.5)	1416 (72.3)

Table 05 : Vital signs and life style
Full Analysis Dataset : CHINA

Variable	Statistics	Cohort 1 Retrospective patients (N=305) (n %)	Cohort 1 Prospective patients (N=495) (n %)	Cohort 2 (N=444) (n %)	Cohort 3 (N=504) (n %)	Cohort 4 (N=530) (n %)	Cohort 5 (N=487) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2460)	Total Prospective patients Cohorts 1 to 4 (N=1973)
	Unknown	-	-	-	7	8	2	17	15
Alcohol Consumption, n(%)	n (missing)	301 (0)	481 (0)	441 (0)	434 (0)	439 (0)	390 (0)	2185 (0)	1795 (0)
	Abstinent	240 (79.7)	366 (76.1)	356 (80.7)	345 (79.5)	342 (77.9)	272 (69.7)	1681 (76.9)	1409 (78.5)
	Light	44 (14.6)	85 (17.7)	56 (12.7)	51 (11.8)	69 (15.7)	78 (20.0)	339 (15.5)	261 (14.5)
	Moderate	13 (4.3)	15 (3.1)	18 (4.1)	25 (5.8)	20 (4.6)	36 (9.2)	114 (5.2)	78 (4.3)
	Heavy	4 (1.3)	15 (3.1)	11 (2.5)	13 (3.0)	8 (1.8)	4 (1.0)	51 (2.3)	47 (2.6)
	Unknown	4	14	3	70	91	97	275	178
Smoker, n(%)	n (missing)	300 (0)	490 (0)	441 (0)	481 (0)	516 (0)	455 (0)	2383 (0)	1928 (0)
	No	203 (67.7)	341 (69.6)	305 (69.2)	340 (70.7)	357 (69.2)	302 (66.4)	1645 (69.0)	1343 (69.7)
	Ex-smoker	57 (19.0)	89 (18.2)	68 (15.4)	53 (11.0)	74 (14.3)	67 (14.7)	351 (14.7)	284 (14.7)
	Current smoker	40 (13.3)	60 (12.2)	68 (15.4)	88 (18.3)	85 (16.5)	86 (18.9)	387 (16.2)	301 (15.6)
	Unknown	5	5	3	23	14	32	77	45

Table 06 : Clinical History
Full Analysis Dataset : CHINA

Variable	Statistics	Cohort 1 Retrospective patients (N=305) (n %)	Cohort 1 Prospective patients (N=495) (n %)	Cohort 2 (N=444) (n %)	Cohort 3 (N=504) (n %)	Cohort 4 (N=530) (n %)	Cohort 5 (N=487) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2460)	Total Prospective patients Cohorts 1 to 4 (N=1973)
Congestive heart failure, n(%)	n (missing)	305 (0)	495 (0)	444 (0)	504 (0)	530 (0)	487 (0)	2460 (0)	1973 (0)
	No	237 (77.7)	400 (80.8)	359 (80.9)	371 (73.6)	425 (80.2)	411 (84.4)	1966 (79.9)	1555 (78.8)
	Yes	68 (22.3)	95 (19.2)	85 (19.1)	133 (26.4)	105 (19.8)	76 (15.6)	494 (20.1)	418 (21.2)
Congestive Heart Failure NYHA Class, n(%)	n (missing)	68 (237)	95 (400)	85 (359)	128 (371)	101 (425)	75 (411)	484 (1966)	409 (1555)
	I	3 (4.4)	2 (2.1)	5 (5.9)	25 (19.5)	1 (1.0)	2 (2.7)	35 (7.2)	33 (8.1)
	II	22 (32.4)	28 (29.5)	25 (29.4)	36 (28.1)	43 (42.6)	21 (28.0)	153 (31.6)	132 (32.3)
	III	29 (42.6)	43 (45.3)	30 (35.3)	44 (34.4)	40 (39.6)	36 (48.0)	193 (39.9)	157 (38.4)
	IV	14 (20.6)	22 (23.2)	25 (29.4)	23 (18.0)	17 (16.8)	16 (21.3)	103 (21.3)	87 (21.3)
	Unknown	-	-	-	5	4	1	10	9
Coronary artery disease, n(%)	n (missing)	305 (0)	495 (0)	444 (0)	504 (0)	530 (0)	487 (0)	2460 (0)	1973 (0)
	No	204 (66.9)	337 (68.1)	297 (66.9)	317 (62.9)	296 (55.8)	282 (57.9)	1529 (62.2)	1247 (63.2)
	Yes	101 (33.1)	158 (31.9)	147 (33.1)	187 (37.1)	234 (44.2)	205 (42.1)	931 (37.8)	726 (36.8)
Acute coronary syndrome, n(%)	n (missing)	305 (0)	495 (0)	444 (0)	498 (0)	510 (0)	478 (0)	2425 (0)	1947 (0)
	No	271 (88.9)	424 (85.7)	364 (82.0)	420 (84.3)	437 (85.7)	408 (85.4)	2053 (84.7)	1645 (84.5)
	Yes	34 (11.1)	71 (14.3)	80 (18.0)	78 (15.7)	73 (14.3)	70 (14.6)	372 (15.3)	302 (15.5)
	Unknown	-	-	-	6	20	9	35	26
Carotid Occlusive Disease, n(%)	n (missing)	305 (0)	495 (0)	444 (0)	477 (0)	506 (0)	462 (0)	2384 (0)	1922 (0)
	No	299 (98.0)	486 (98.2)	438 (98.6)	448 (93.9)	486 (96.0)	428 (92.6)	2286 (95.9)	1858 (96.7)

Table 06 : Clinical History
Full Analysis Dataset : CHINA

Variable	Statistics	Cohort 1 Retrospective patients (N=305) (n %)	Cohort 1 Prospective patients (N=495) (n %)	Cohort 2 (N=444) (n %)	Cohort 3 (N=504) (n %)	Cohort 4 (N=530) (n %)	Cohort 5 (N=487) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2460)	Total Prospective patients Cohorts 1 to 4 (N=1973)
	Yes	6 (2.0)	9 (1.8)	6 (1.4)	29 (6.1)	20 (4.0)	34 (7.4)	98 (4.1)	64 (3.3)
	Unknown	-	-	-	27	24	25	76	51
PE or DVT, n(%)	n (missing)	305 (0)	495 (0)	444 (0)	481 (0)	523 (0)	458 (0)	2401 (0)	1943 (0)
	No	302 (99.0)	492 (99.4)	437 (98.4)	478 (99.4)	520 (99.4)	453 (98.9)	2380 (99.1)	1927 (99.2)
	Yes	3 (1.0)	3 (0.6)	7 (1.6)	3 (0.6)	3 (0.6)	5 (1.1)	21 (0.9)	16 (0.8)
	Unknown	-	-	-	23	7	29	59	30
Other Thromboemboli sm, n(%)	n (missing)	305 (0)	495 (0)	443 (1)	0 (504)	0 (530)	0 (487)	938 (1522)	938 (1035)
	No	302 (99.0)	489 (98.8)	440 (99.3)	-	-	-	929 (99.0)	929 (99.0)
	Yes	3 (1.0)	6 (1.2)	3 (0.7)	-	-	-	9 (1.0)	9 (1.0)
Systemic Embolization, n(%)	n (missing)	305 (0)	495 (0)	444 (0)	482 (0)	523 (0)	462 (0)	2406 (0)	1944 (0)
	No	305 (100.0)	492 (99.4)	443 (99.8)	480 (99.6)	522 (99.8)	461 (99.8)	2398 (99.7)	1937 (99.6)
	Yes	-	3 (0.6)	1 (0.2)	2 (0.4)	1 (0.2)	1 (0.2)	8 (0.3)	7 (0.4)
	Unknown	-	-	-	22	7	25	54	29
Coronary Artery Bypass Graft, n(%)	n (missing)	279 (0)	461 (0)	444 (0)	483 (0)	523 (0)	470 (0)	2381 (0)	1911 (0)
	No	277 (99.3)	458 (99.3)	442 (99.5)	477 (98.8)	519 (99.2)	468 (99.6)	2364 (99.3)	1896 (99.2)
	Yes	2 (0.7)	3 (0.7)	2 (0.5)	6 (1.2)	4 (0.8)	2 (0.4)	17 (0.7)	15 (0.8)
	Unknown	26	34	-	21	7	17	79	62
Stroke/TIA, n(%)	n (missing)	305 (0)	495 (0)	444 (0)	504 (0)	530 (0)	487 (0)	2460 (0)	1973 (0)

Table 06 : Clinical History
Full Analysis Dataset : CHINA

Variable	Statistics	Cohort 1 Retrospective patients (N=305) (n %)	Cohort 1 Prospective patients (N=495) (n %)	Cohort 2 (N=444) (n %)	Cohort 3 (N=504) (n %)	Cohort 4 (N=530) (n %)	Cohort 5 (N=487) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2460)	Total Prospective patients Cohorts 1 to 4 (N=1973)
	No	255 (83.6)	429 (86.7)	374 (84.2)	419 (83.1)	442 (83.4)	402 (82.5)	2066 (84.0)	1664 (84.3)
	Yes	50 (16.4)	66 (13.3)	70 (15.8)	85 (16.9)	88 (16.6)	85 (17.5)	394 (16.0)	309 (15.7)
Stroke, n(%)	n (missing)	305 (0)	495 (0)	444 (0)	481 (0)	523 (0)	464 (0)	2407 (0)	1943 (0)
	No	275 (90.2)	451 (91.1)	388 (87.4)	438 (91.1)	452 (86.4)	412 (88.8)	2141 (88.9)	1729 (89.0)
	Yes	30 (9.8)	44 (8.9)	56 (12.6)	43 (8.9)	71 (13.6)	52 (11.2)	266 (11.1)	214 (11.0)
	Unknown	-	-	-	23	7	23	53	30
History of Bleeding, n(%)	n (missing)	305 (0)	495 (0)	444 (0)	482 (0)	524 (0)	466 (0)	2411 (0)	1945 (0)
	No	297 (97.4)	480 (97.0)	430 (96.8)	472 (97.9)	516 (98.5)	463 (99.4)	2361 (97.9)	1898 (97.6)
	Yes	8 (2.6)	15 (3.0)	14 (3.2)	10 (2.1)	8 (1.5)	3 (0.6)	50 (2.1)	47 (2.4)
	Unknown	-	-	-	22	6	21	49	28
Hypercholester olaemia, n(%)	n (missing)	305 (0)	495 (0)	444 (0)	472 (0)	493 (0)	475 (0)	2379 (0)	1904 (0)
	No	248 (81.3)	400 (80.8)	354 (79.7)	358 (75.8)	393 (79.7)	386 (81.3)	1891 (79.5)	1505 (79.0)
	Yes	57 (18.7)	95 (19.2)	90 (20.3)	114 (24.2)	100 (20.3)	89 (18.7)	488 (20.5)	399 (21.0)
	Unknown	-	-	-	32	37	12	81	69
Diabetes, n(%)	n (missing)	305 (0)	495 (0)	444 (0)	504 (0)	530 (0)	487 (0)	2460 (0)	1973 (0)
	No	247 (81.0)	417 (84.2)	350 (78.8)	411 (81.5)	414 (78.1)	388 (79.7)	1980 (80.5)	1592 (80.7)
	Type I	1 (0.3)	-	-	2 (0.4)	5 (0.9)	3 (0.6)	10 (0.4)	7 (0.4)
	Type II	57 (18.7)	78 (15.8)	94 (21.2)	91 (18.1)	111 (20.9)	96 (19.7)	470 (19.1)	374 (19.0)
Diabetes, n(%)	n (missing)	305 (0)	495 (0)	444 (0)	504 (0)	530 (0)	487 (0)	2460 (0)	1973 (0)
	No	247 (81.0)	417 (84.2)	350 (78.8)	411 (81.5)	414 (78.1)	388 (79.7)	1980 (80.5)	1592 (80.7)
	Yes	58 (19.0)	78 (15.8)	94 (21.2)	93 (18.5)	116 (21.9)	99 (20.3)	480 (19.5)	381 (19.3)
Cirrhosis, n(%)	n (missing)	305 (0)	495 (0)	444 (0)	482 (0)	517 (0)	471 (0)	2409 (0)	1938 (0)
	No	304 (99.7)	493 (99.6)	441 (99.3)	479 (99.4)	516 (99.8)	471 (100.0)	2400 (99.6)	1929 (99.5)

Table 06 : Clinical History
Full Analysis Dataset : CHINA

Variable	Statistics	Cohort 1 Retrospective patients (N=305) (n %)	Cohort 1 Prospective patients (N=495) (n %)	Cohort 2 (N=444) (n %)	Cohort 3 (N=504) (n %)	Cohort 4 (N=530) (n %)	Cohort 5 (N=487) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2460)	Total Prospective patients Cohorts 1 to 4 (N=1973)
	Yes	1 (0.3)	2 (0.4)	3 (0.7)	3 (0.6)	1 (0.2)	-	9 (0.4)	9 (0.5)
	Unknown	-	-	-	22	13	16	51	35
Dementia, n(%)	n (missing)	305 (0)	495 (0)	444 (0)	483 (0)	524 (0)	481 (0)	2427 (0)	1946 (0)
	No	304 (99.7)	493 (99.6)	444 (100.0)	480 (99.4)	524 (100.0)	480 (99.8)	2421 (99.8)	1941 (99.7)
	Yes	1 (0.3)	2 (0.4)	-	3 (0.6)	-	1 (0.2)	6 (0.2)	5 (0.3)
	Unknown	-	-	-	21	6	6	33	27
Hyperthyroidis m, n(%)	n (missing)	305 (0)	495 (0)	444 (0)	472 (0)	518 (0)	477 (0)	2406 (0)	1929 (0)
	No	300 (98.4)	481 (97.2)	433 (97.5)	461 (97.7)	505 (97.5)	466 (97.7)	2346 (97.5)	1880 (97.5)
	Yes	5 (1.6)	14 (2.8)	11 (2.5)	11 (2.3)	13 (2.5)	11 (2.3)	60 (2.5)	49 (2.5)
	Unknown	-	-	-	32	12	10	54	44
Hypothyroidism, n (missing) n(%)	n (missing)	305 (0)	495 (0)	444 (0)	472 (0)	519 (0)	476 (1)	2406 (1)	1930 (0)
	No	302 (99.0)	490 (99.0)	439 (98.9)	458 (97.0)	504 (97.1)	468 (98.3)	2359 (98.0)	1891 (98.0)
	Yes	3 (1.0)	5 (1.0)	5 (1.1)	14 (3.0)	15 (2.9)	8 (1.7)	47 (2.0)	39 (2.0)
	Unknown	-	-	-	32	11	10	53	43
Vascular Disease, n(%)	n (missing)	305 (0)	495 (0)	444 (0)	503 (1)	523 (7)	481 (6)	2446 (14)	1965 (8)
	No	260 (85.2)	408 (82.4)	345 (77.7)	379 (75.3)	380 (72.7)	348 (72.3)	1860 (76.0)	1512 (76.9)
	Yes	45 (14.8)	87 (17.6)	99 (22.3)	124 (24.7)	143 (27.3)	133 (27.7)	586 (24.0)	453 (23.1)
Moderate to Severe CKD, n(%)	n (missing)	305 (0)	495 (0)	444 (0)	504 (0)	530 (0)	487 (0)	2460 (0)	1973 (0)
	No	296 (97.0)	478 (96.6)	425 (95.7)	486 (96.4)	507 (95.7)	472 (96.9)	2368 (96.3)	1896 (96.1)
	Yes	9 (3.0)	17 (3.4)	19 (4.3)	18 (3.6)	23 (4.3)	15 (3.1)	92 (3.7)	77 (3.9)

Study ID: TRI08888

GARFIELD: International Registry of Patients Newly Diagnosed with AF

Table 06 : Clinical History
Full Analysis Dataset : CHINA

**Table 07 : Treatment for stroke prophylaxis
Full Analysis Dataset : CHINA**

Variable	Statistics	Cohort 1 Retrospective patients (N=305) (n %)	Cohort 1 Prospective patients (N=495) (n %)	Cohort 2 (N=444) (n %)	Cohort 3 (N=504) (n %)	Cohort 4 (N=530) (n %)	Cohort 5 (N=487) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2460)	Total Prospective patients Cohorts 1 to 4 (N=1973)
Baseline Treatment, n(%)	n (missing)	298 (0)	481 (0)	444 (0)	502 (0)	526 (0)	482 (0)	2435 (0)	1953 (0)
	VKA	66 (22.1)	71 (14.8)	77 (17.3)	97 (19.3)	113 (21.5)	106 (22.0)	464 (19.1)	358 (18.3)
	VKA+AP	21 (7.0)	18 (3.7)	24 (5.4)	37 (7.4)	35 (6.7)	32 (6.6)	146 (6.0)	114 (5.8)
	FXA	-	-	-	1 (0.2)	21 (4.0)	10 (2.1)	32 (1.3)	22 (1.1)
	FXA+AP	2 (0.7)	10 (2.1)	4 (0.9)	3 (0.6)	12 (2.3)	5 (1.0)	34 (1.4)	29 (1.5)
	DTI	-	1 (0.2)	-	3 (0.6)	2 (0.4)	36 (7.5)	42 (1.7)	6 (0.3)
	DTI+AP	6 (2.0)	17 (3.5)	1 (0.2)	3 (0.6)	4 (0.8)	1 (0.2)	26 (1.1)	25 (1.3)
	AP	162 (54.4)	293 (60.9)	267 (60.1)	253 (50.4)	259 (49.2)	234 (48.5)	1306 (53.6)	1072 (54.9)
	NONE	41 (13.8)	71 (14.8)	71 (16.0)	105 (20.9)	80 (15.2)	58 (12.0)	385 (15.8)	327 (16.7)
	Unknown	7	14	-	2	4	5	25	20
	VKA±AP	87 (29.2)	89 (18.5)	101 (22.7)	134 (26.7)	148 (28.1)	138 (28.6)	610 (25.1)	472 (24.2)
	FXA±AP	2 (0.7)	10 (2.1)	4 (0.9)	4 (0.8)	33 (6.3)	15 (3.1)	66 (2.7)	51 (2.6)
	DTI±AP	6 (2.0)	18 (3.7)	1 (0.2)	6 (1.2)	6 (1.1)	37 (7.7)	68 (2.8)	31 (1.6)
	FXA/DTI	-	1 (0.2)	-	4 (0.8)	23 (4.4)	46 (9.5)	74 (3.0)	28 (1.4)
	FXA/DTI+AP	8 (2.7)	27 (5.6)	5 (1.1)	6 (1.2)	16 (3.0)	6 (1.2)	60 (2.5)	54 (2.8)
	FXA/DTI±AP	8 (2.7)	28 (5.8)	5 (1.1)	10 (2.0)	39 (7.4)	52 (10.8)	134 (5.5)	82 (4.2)
	AC	66 (22.1)	72 (15.0)	77 (17.3)	101 (20.1)	136 (25.9)	152 (31.5)	538 (22.1)	386 (19.8)
	AC+AP	29 (9.7)	45 (9.4)	29 (6.5)	43 (8.6)	51 (9.7)	38 (7.9)	206 (8.5)	168 (8.6)
	AC±AP	95 (31.9)	117 (24.3)	106 (23.9)	144 (28.7)	187 (35.6)	190 (39.4)	744 (30.6)	554 (28.4)

Table 08: Treatment
Full Analysis Dataset : CHINA

	Cohort 1 Retrospective (N=305) (n %)	Cohort 1 Prospective (N=495) (n %)	Cohort 2 (N=444) (n %)	Cohort 3 (N=504) (n %)	Cohort 4 (N=530) (n %)	Cohort 5 (N=487) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2460)	Total Prospective patients Cohorts 1 to 4 (N=1973)
Anti-platelet (non mutually exclusive groups)								
Glycoprotein inhibitors	2 (0.7)	3 (0.6)	2 (0.5)	-	-		5 (0.2)	5 (0.3)
ADP receptor/P2Y12 inhibitors	38 (12.5)	71 (14.3)	98 (22.1)	104 (20.6)	127 (24.0)	129 (26.5)	529 (21.5)	400 (20.3)
Prostaglandin Cox inhibitors	2 (0.7)	4 (0.8)	2 (0.5)	2 (0.4)	1 (0.2)	3 (0.6)	12 (0.5)	9 (0.5)
ASA	32 (10.5)	52 (10.5)	-	35 (6.9)	9 (1.7)	20 (4.1)	116 (4.7)	96 (4.9)
	109 (35.7)	233 (47.1)	278 (62.6)	241 (47.8)	275 (51.9)	224 (46.0)	1251 (50.9)	1027 (52.1)
Anticoagulant drugs (non mutually exclusive groups)								
VKA	92 (30.2)	98 (19.8)	101 (22.7)	136 (27.0)	151 (28.5)	142 (29.2)	628 (25.5)	486 (24.6)
FXa	2 (0.7)	13 (2.6)	4 (0.9)	5 (1.0)	35 (6.6)	18 (3.7)	75 (3.0)	57 (2.9)
DTI	11 (3.6)	28 (5.7)	1 (0.2)	7 (1.4)	9 (1.7)	41 (8.4)	86 (3.5)	45 (2.3)
Heparinoid	2 (0.7)	7 (1.4)	10 (2.3)	2 (0.4)	13 (2.5)	11 (2.3)	43 (1.7)	32 (1.6)
Heparins	1 (0.3)	8 (1.6)	29 (6.5)	54 (10.7)	18 (3.4)	44 (9.0)	153 (6.2)	109 (5.5)
Other	-	-	-	-	1 (0.2)	3 (0.6)	4 (0.2)	1 (0.1)

**Table 09 : Risk scores
Full Analysis Dataset : CHINA**

Variable	Statistics	Cohort 1 Retrospective patients (N=305) (n %)	Cohort 1 Prospective patients (N=495) (n %)	Cohort 2 (N=444) (n %)	Cohort 3 (N=504) (n %)	Cohort 4 (N=530) (n %)	Cohort 5 (N=487) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2460)	Total Prospective patients Cohorts 1 to 4 (N=1973)
CHADS2 Score	n (missing)	295 (10)	484 (11)	434 (10)	496 (8)	521 (9)	485 (2)	2420 (40)	1935 (38)
	Mean (SD)	1.7 (1.1)	1.6 (1.1)	1.8 (1.1)	1.8 (1.2)	1.8 (1.2)	1.7 (1.2)	1.8 (1.1)	1.8 (1.1)
	Median (IQR)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)
	Min to Max	0 to 5	0 to 6	0 to 6	0 to 5	0 to 6	0 to 6	0 to 6	0 to 6
CHADS2 score categories, n(%)	n (missing)	295 (10)	484 (11)	434 (10)	496 (8)	521 (9)	485 (2)	2420 (40)	1935 (38)
	0	24 (8.1)	46 (9.5)	23 (5.3)	42 (8.5)	44 (8.4)	51 (10.5)	206 (8.5)	155 (8.0)
	1	125 (42.4)	210 (43.4)	186 (42.9)	185 (37.3)	194 (37.2)	194 (40.0)	969 (40.0)	775 (40.1)
	2	82 (27.8)	144 (29.8)	123 (28.3)	135 (27.2)	155 (29.8)	135 (27.8)	692 (28.6)	557 (28.8)
	3	39 (13.2)	58 (12.0)	66 (15.2)	88 (17.7)	85 (16.3)	64 (13.2)	361 (14.9)	297 (15.3)
	4	19 (6.4)	19 (3.9)	30 (6.9)	34 (6.9)	26 (5.0)	27 (5.6)	136 (5.6)	109 (5.6)
	5	6 (2.0)	5 (1.0)	5 (1.2)	12 (2.4)	16 (3.1)	13 (2.7)	51 (2.1)	38 (2.0)
	6	-	2 (0.4)	1 (0.2)	-	1 (0.2)	1 (0.2)	5 (0.2)	4 (0.2)
CHA2DS2- VASc Score	n (missing)	295 (10)	484 (11)	434 (10)	495 (9)	514 (16)	476 (11)	2403 (57)	1927 (46)
	Mean (SD)	2.9 (1.6)	2.8 (1.5)	3.1 (1.7)	3.2 (1.7)	3.2 (1.7)	3.0 (1.7)	3.1 (1.7)	3.1 (1.7)
	Median (IQR)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)
	Min to Max	0 to 8	0 to 8	0 to 8	0 to 8	0 to 8	0 to 9	0 to 9	0 to 8
CHA2DS2- VASc score categories, n(%)	n (missing)	295 (10)	484 (11)	434 (10)	495 (9)	514 (16)	476 (11)	2403 (57)	1927 (46)
	0	11 (3.7)	16 (3.3)	13 (3.0)	15 (3.0)	11 (2.1)	13 (2.7)	68 (2.8)	55 (2.9)
	1	57 (19.3)	85 (17.6)	71 (16.4)	73 (14.7)	73 (14.2)	80 (16.8)	382 (15.9)	302 (15.7)
	2	60 (20.3)	116 (24.0)	82 (18.9)	96 (19.4)	110 (21.4)	110 (23.1)	514 (21.4)	404 (21.0)
	3	66 (22.4)	112 (23.1)	108 (24.9)	117 (23.6)	116 (22.6)	100 (21.0)	553 (23.0)	453 (23.5)
	4	52 (17.6)	85 (17.6)	68 (15.7)	86 (17.4)	95 (18.5)	81 (17.0)	415 (17.3)	334 (17.3)

Table 09 : Risk scores
Full Analysis Dataset : CHINA

Variable	Statistics	Cohort 1 Retrospective patients (N=305) (n %)	Cohort 1 Prospective patients (N=495) (n %)	Cohort 2 (N=444) (n %)	Cohort 3 (N=504) (n %)	Cohort 4 (N=530) (n %)	Cohort 5 (N=487) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2460)	Total Prospective patients Cohorts 1 to 4 (N=1973)
	5	29 (9.8)	44 (9.1)	59 (13.6)	53 (10.7)	62 (12.1)	51 (10.7)	269 (11.2)	218 (11.3)
	6-9	20 (6.8)	26 (5.4)	33 (7.6)	55 (11.1)	47 (9.1)	41 (8.6)	202 (8.4)	161 (8.4)
HAS-BLED score	n (missing)	212 (93)	369 (126)	390 (54)	407 (97)	429 (101)	385 (102)	1980 (480)	1595 (378)
	Mean (SD)	1.6 (0.9)	1.6 (0.9)	1.6 (0.9)	1.5 (1.0)	1.5 (0.9)	1.4 (0.9)	1.5 (0.9)	1.5 (0.9)
	Median (IQR)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)
	Min to Max	0 to 5	0 to 5	0 to 4	0 to 4	0 to 5	0 to 4	0 to 5	0 to 5
HAS-BLED score categories, n(%)	n (missing)	212 (93)	369 (126)	390 (54)	407 (97)	429 (101)	385 (102)	1980 (480)	1595 (378)
	0	24 (11.3)	37 (10.0)	30 (7.7)	65 (16.0)	61 (14.2)	54 (14.0)	247 (12.5)	193 (12.1)
	1	71 (33.5)	123 (33.3)	157 (40.3)	146 (35.9)	143 (33.3)	150 (39.0)	719 (36.3)	569 (35.7)
	2	94 (44.3)	163 (44.2)	147 (37.7)	143 (35.1)	181 (42.2)	139 (36.1)	773 (39.0)	634 (39.7)
	3	19 (9.0)	38 (10.3)	50 (12.8)	41 (10.1)	40 (9.3)	40 (10.4)	209 (10.6)	169 (10.6)
	4	3 (1.4)	5 (1.4)	6 (1.5)	12 (2.9)	3 (0.7)	2 (0.5)	28 (1.4)	26 (1.6)
	5	1 (0.5)	3 (0.8)	-	-	1 (0.2)	-	4 (0.2)	4 (0.3)

Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : CHINA

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Cohort 1 retrospective	0	6	54.5	-	-	-	-	-	-	-	-	-	-	5	45.5	-	-	-
	1	16	29.1	2	3.6	-	-	1	1.8	-	-	-	-	27	49.1	9	16.4	2
	2	12	20.7	2	3.4	-	-	-	-	-	-	2	3.4	32	55.2	10	17.2	2
	3	7	10.9	5	7.8	-	-	-	-	-	-	2	3.1	39	60.9	11	17.2	2
	4	11	21.2	8	15.4	-	-	-	-	-	-	-	-	27	51.9	6	11.5	-
	5	11	37.9	2	6.9	-	-	-	-	-	-	-	-	15	51.7	1	3.4	-
	6-9	3	15.8	2	10.5	-	-	1	5.3	-	-	2	10.5	11	57.9	-	-	1
Cohort 1 prospective	0	4	25	-	-	-	-	-	-	-	-	-	-	6	37.5	6	37.5	-
	1	18	21.7	1	1.2	-	-	-	-	1	1.2	2	2.4	51	61.4	10	12	2
	2	20	17.9	5	4.5	-	-	1	0.9	-	-	2	1.8	65	58	19	17	4
	3	8	7.3	6	5.5	-	-	3	2.7	-	-	3	2.7	75	68.2	15	13.6	2
	4	13	16	5	6.2	-	-	4	4.9	-	-	5	6.2	46	56.8	8	9.9	4
	5	5	11.9	1	2.4	-	-	1	2.4	-	-	3	7.1	29	69	3	7.1	2
	6-9	2	7.7	-	-	-	-	1	3.8	-	-	2	7.7	17	65.4	4	15.4	-
Cohort 2	0	3	23.1	-	-	-	-	-	-	-	-	-	-	8	61.5	2	15.4	-
	1	14	19.7	7	9.9	-	-	-	-	-	-	-	-	37	52.1	13	18.3	-
	2	19	23.2	5	6.1	-	-	-	-	-	-	-	-	46	56.1	12	14.6	-
	3	17	15.7	4	3.7	-	-	2	1.9	-	-	-	-	66	61.1	19	17.6	-
	4	10	14.7	3	4.4	-	-	-	-	-	-	-	-	45	66.2	10	14.7	-
	5	9	15.3	2	3.4	-	-	-	-	-	-	-	-	41	69.5	7	11.9	-
	6-9	4	12.1	3	9.1	-	-	2	6.1	-	-	1	3	18	54.5	5	15.2	-
Cohort 3	0	4	26.7	2	13.3	-	-	-	-	-	-	-	-	5	33.3	4	26.7	-
	1	13	18.1	3	4.2	-	-	-	-	2	2.8	-	-	28	38.9	26	36.1	1
	2	16	16.7	5	5.2	1	1	1	1	-	-	1	1	45	46.9	27	28.1	-
	3	28	23.9	9	7.7	-	-	1	0.9	-	-	1	0.9	55	47	23	19.7	-
	4	15	17.4	9	10.5	-	-	-	-	1	1.2	1	1.2	47	54.7	13	15.1	-

Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : CHINA

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
	5	11	20.8	3	5.7	-	-	1	1.9	-	-	-	-	28	52.8	10	18.9	-
	6-9	9	16.7	6	11.1	-	-	-	-	-	-	-	-	38	70.4	1	1.9	1
Cohort 4	0	4	36.4	-	-	1	9.1	-	-	-	-	-	-	4	36.4	2	18.2	-
	1	21	28.8	1	1.4	2	2.7	-	-	1	1.4	1	1.4	29	39.7	18	24.7	-
	2	22	20.4	8	7.4	4	3.7	3	2.8	-	-	-	-	57	52.8	14	13	2
	3	25	21.9	6	5.3	11	9.6	1	0.9	1	0.9	-	-	56	49.1	14	12.3	2
	4	17	17.9	9	9.5	1	1.1	4	4.2	-	-	2	2.1	49	51.6	13	13.7	-
	5	15	24.2	5	8.1	1	1.6	2	3.2	-	-	1	1.6	34	54.8	4	6.5	-
	6-9	6	12.8	5	10.6	1	2.1	2	4.3	-	-	-	-	29	61.7	4	8.5	-
Cohort 5	0	4	30.8	1	7.7	-	-	-	-	-	-	-	-	4	30.8	4	30.8	-
	1	13	16.3	8	10	4	5	-	-	8	10	-	-	36	45	11	13.8	-
	2	22	20.2	5	4.6	2	1.8	1	0.9	11	10.1	1	0.9	53	48.6	14	12.8	1
	3	23	23.2	4	4	1	1	1	1	6	6.1	-	-	53	53.5	11	11.1	1
	4	23	28.8	4	5	2	2.5	3	3.8	6	7.5	-	-	34	42.5	8	10	1
	5	13	26.5	5	10.2	1	2	-	-	1	2	-	-	26	53.1	3	6.1	2
	6-9	7	17.1	5	12.2	-	-	-	-	3	7.3	-	-	22	53.7	4	9.8	-
Total Prospective patients Cohorts 1 to 5	0	19	27.9	3	4.4	1	1.5	-	-	-	-	-	-	27	39.7	18	26.5	-
	1	79	20.8	20	5.3	6	1.6	-	-	12	3.2	3	0.8	181	47.8	78	20.6	3
	2	99	19.5	28	5.5	7	1.4	6	1.2	11	2.2	4	0.8	266	52.5	86	17	7
	3	101	18.4	29	5.3	12	2.2	8	1.5	7	1.3	4	0.7	305	55.7	82	15	5
	4	78	19	30	7.3	3	0.7	11	2.7	7	1.7	8	2	221	53.9	52	12.7	5
	5	53	20	16	6	2	0.8	4	1.5	1	0.4	4	1.5	158	59.6	27	10.2	4
	6-9	28	13.9	19	9.5	1	0.5	5	2.5	3	1.5	3	1.5	124	61.7	18	9	1

**Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : CHINA**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	
Total	0	15	27.3	2	3.6	1	1.8	-	-	-	-	-	-	23	41.8	14	25.5	-	
Prospective patients																			
Cohorts 1 to 4																			
	1	66	22.1	12	4	2	0.7	-	-	4	1.3	3	1	145	48.5	67	22.4	3	
	2	77	19.3	23	5.8	5	1.3	5	1.3	-	-	3	0.8	213	53.5	72	18.1	6	
	3	78	17.4	25	5.6	11	2.4	7	1.6	1	0.2	4	0.9	252	56.1	71	15.8	4	
	4	55	16.7	26	7.9	1	0.3	8	2.4	1	0.3	8	2.4	187	56.7	44	13.3	4	
	5	40	18.5	11	5.1	1	0.5	4	1.9	-	-	4	1.9	132	61.1	24	11.1	2	
	6-9	21	13.1	14	8.8	1	0.6	5	3.1	-	-	3	1.9	102	63.8	14	8.8	1	

**Table 11: Treatment at baseline by HAS-BLED score
Full Analysis Dataset : CHINA**

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Cohort 1 retrospective	0	15	62.5	-	-	-	-	-	-	-	-	-	-	-	-	9	37.5	-
	1	20	29	5	7.2	-	-	1	1.4	-	-	1	1.4	32	46.4	10	14.5	2
	2	8	8.8	6	6.6	-	-	-	-	-	-	2	2.2	69	75.8	6	6.6	3
	3	1	5.6	2	11.1	-	-	1	5.6	-	-	3	16.7	11	61.1	-	-	1
	4-9	-	-	1	25	-	-	-	-	-	-	-	-	3	75	-	-	-
Cohort 1 prospective	0	25	69.4	-	-	-	-	-	-	-	-	-	-	-	-	11	30.6	1
	1	20	16.7	7	5.8	-	-	1	0.8	1	0.8	5	4.2	63	52.5	23	19.2	3
	2	8	5.1	6	3.8	-	-	5	3.2	-	-	6	3.8	127	80.4	6	3.8	5
	3	2	5.7	2	5.7	-	-	2	5.7	-	-	5	14.3	22	62.9	2	5.7	3
	4-9	-	-	-	-	-	-	1	12.5	-	-	1	12.5	6	75	-	-	-
Cohort 2	0	12	40	-	-	-	-	-	-	-	-	-	-	-	-	18	60	-
	1	44	28	7	4.5	-	-	-	-	-	-	-	-	72	45.9	34	21.7	-
	2	10	6.8	10	6.8	-	-	-	-	-	-	-	-	115	78.2	12	8.2	-
	3	2	4	2	4	-	-	1	2	-	-	1	2	43	86	1	2	-
	4-9	-	-	1	16.7	-	-	-	-	-	-	-	-	5	83.3	-	-	-
Cohort 3	0	23	35.9	-	-	1	1.6	-	-	2	3.1	-	-	-	-	38	59.4	1
	1	53	36.6	8	5.5	-	-	-	-	-	-	-	-	49	33.8	35	24.1	1
	2	11	7.7	15	10.5	-	-	1	0.7	-	-	1	0.7	102	71.3	13	9.1	-
	3	2	4.9	5	12.2	-	-	-	-	-	-	1	2.4	31	75.6	2	4.9	-
	4-9	-	-	-	-	-	-	-	-	-	-	-	-	12	100	-	-	-
Cohort 4	0	38	63.3	-	-	3	5	-	-	1	1.7	-	-	-	-	18	30	1
	1	33	23.1	8	5.6	5	3.5	1	0.7	-	-	1	0.7	67	46.9	28	19.6	-
	2	23	12.8	17	9.4	4	2.2	4	2.2	1	0.6	2	1.1	116	64.4	13	7.2	1
	3	1	2.5	1	2.5	-	-	2	5	-	-	1	2.5	34	85	1	2.5	-
	4-9	-	-	1	25	-	-	-	-	-	-	-	-	3	75	-	-	-

**Table 11: Treatment at baseline by HAS-BLED score
Full Analysis Dataset : CHINA**

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Cohort 5	0	22	41.5	-	-	4	7.5	-	-	13	24.5	-	-	-	-	14	26.4	1
	1	43	28.7	8	5.3	3	2	1	0.7	12	8	1	0.7	64	42.7	18	12	-
	2	14	10.4	8	5.9	2	1.5	4	3	5	3.7	-	-	97	71.9	5	3.7	4
	3	4	10	5	12.5	1	2.5	-	-	1	2.5	-	-	28	70	1	2.5	-
	4-9	-	-	1	50	-	-	-	-	-	-	-	-	-	1	50	-	-
Total Prospective patients Cohorts 1 to 5	0	120	49.4	-	-	8	3.3	-	-	16	6.6	-	-	-	-	99	40.7	4
Total Prospective patients Cohorts 1 to 4	1	193	27	38	5.3	8	1.1	3	0.4	13	1.8	7	1	315	44.1	138	19.3	4
	2	66	8.7	56	7.3	6	0.8	14	1.8	6	0.8	9	1.2	557	73	49	6.4	10
	3	11	5.3	15	7.3	1	0.5	5	2.4	1	0.5	8	3.9	158	76.7	7	3.4	3
	4-9	-	-	3	9.4	-	-	1	3.1	-	-	1	3.1	27	84.4	-	-	-
	0	98	51.6	-	-	4	2.1	-	-	3	1.6	-	-	-	-	85	44.7	3
Total Prospective patients Cohorts 1 to 4	1	150	26.5	30	5.3	5	0.9	2	0.4	1	0.2	6	1.1	251	44.4	120	21.2	4
	2	52	8.3	48	7.6	4	0.6	10	1.6	1	0.2	9	1.4	460	73.2	44	7	6
	3	7	4.2	10	6	-	-	5	3	-	-	8	4.8	130	78.3	6	3.6	3
	4-9	-	-	2	6.7	-	-	1	3.3	-	-	1	3.3	26	86.7	-	-	-
	0	98	51.6	-	-	4	2.1	-	-	3	1.6	-	-	-	-	85	44.7	3

**Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : CHINA**

Variable	Statistics	Cohort 1 Prospective patients (N=89) (n %)	Cohort 2 (N=101) (n %)	Cohort 3 (N=134) (n %)	Cohort 4 (N=148) (n %)	Total Prospective patients Cohorts 1 to 4 (N=472)
TTR value, n(%)	n (missing)	11 (78)	21 (80)	25 (109)	14 (134)	71 (401)
	<65	7 (63.6)	17 (81.0)	21 (84.0)	13 (92.9)	58 (81.7)
	>=65	4 (36.4)	4 (19.0)	4 (16.0)	1 (7.1)	13 (18.3)
TTR	n (missing)	11 (78)	21 (80)	25 (109)	14 (134)	71 (401)
	Mean (SD)	47.7 (33.8)	33.6 (31.2)	28.9 (32.2)	22.6 (22.9)	32.0 (30.9)
	Median (IQR)	39.5 (21.7 to 78.5)	21.0 (8.5 to 47.5)	19.8 (0.0 to 48.3)	17.5 (4.2 to 45.9)	21.0 (3.2 to 51.7)
	Min to Max	0.0 to 100.0	0.0 to 100.0	0.0 to 100.0	0.0 to 70.2	0.0 to 100.0
INR value, n(%)	n	84	128	158	100	470
	2-3	28 (33.3)	37 (28.9)	44 (27.8)	30 (30.0)	139 (29.6)
	<2	50 (59.5)	77 (60.2)	103 (65.2)	61 (61.0)	291 (61.9)
	>3	6 (7.1)	14 (10.9)	11 (7.0)	9 (9.0)	40 (8.5)
INR	n	84	128	158	100	470
	Mean (SD)	2.0 (0.8)	2.0 (0.8)	1.8 (0.7)	2.0 (1.0)	1.9 (0.8)
	Median (IQR)	1.9 (1.5 to 2.3)	1.8 (1.4 to 2.2)	1.7 (1.3 to 2.1)	1.9 (1.3 to 2.1)	1.8 (1.3 to 2.2)
	Min to Max	1.0 to 5.5	0.8 to 4.8	0.9 to 4.3	0.9 to 8.3	0.8 to 8.3

**Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : CHINA**

Outcome	Cause	N	Events	Event rate /100 person-years	95% CI
All-cause death		1973	64	3.45	(2.70 to 4.41)
	Cardiovascular death	1973	32	1.73	(1.22 to 2.44)
	Non-Cardiovascular death	1973	13	0.70	(0.41 to 1.21)
	Undetermined cause	1973	19	1.03	(0.65 to 1.61)
Stroke/SE		1973	25	1.36	(0.92 to 2.01)
Major bleed		1973	5	0.27	(0.11 to 0.65)
Acute coronary syndrome		1973	10	0.54	(0.29 to 1.00)
Congestive Heart Failure		1973	19	1.03	(0.66 to 1.62)

**Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : CHINA**

Outcome	Cause	CHINA		
		N	Events	%
Cardiovascular causes	Myocardial infarction	32	5	15.63
	Ischaemic stroke	32	2	6.25
	Congestive heart failure	32	16	50.00
	Sudden or unwitnessed death	32	5	15.63
	Other	32	4	12.50
Non-cardiovascular causes	Respiratory failure	13	5	38.46
	Infection/sepsis	13	2	15.39
	Malignancy	13	1	7.69
	Other	13	5	38.46

**Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset :CHINA**

OUTCOME	CHINA		
	N	Events	%
Stroke(not including systemic embolism)	1973	24	1.22
Primary Ischemic Stroke	1973	19	0.96
<i>of which secondary hemorrhagic ischemic</i>	1973	1	0.05
Undetermined	1973	5	0.25

**Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : CHINA**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	55	51.29	1	1.95	(0.28 to 13.84)
1	302	290.48	4	1.38	(0.52 to 3.67)
2	404	383.81	7	1.82	(0.87 to 3.83)
3	453	428.38	10	2.33	(1.26 to 4.34)
4+	713	658.56	40	6.07	(4.46 to 8.28)
Unknown	46	40.55	2	4.93	(1.23 to 19.72)

**Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : CHINA**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	55	51.29	0	-	-
1	302	288.88	2	0.69	(0.17 to 2.77)
2	404	383.15	1	0.26	(0.04 to 1.85)
3	453	422.22	12	2.84	(1.61 to 5.01)
4+	713	654.40	9	1.38	(0.72 to 2.64)
Unknown	46	40.52	1	2.47	(0.35 to 17.52)

**Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : CHINA**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	55	51.29	0	-	-
1	302	290.48	0	-	-
2	404	383.13	1	0.26	(0.04 to 1.85)
3	453	426.82	2	0.47	(0.12 to 1.87)
4+	713	657.90	2	0.30	(0.08 to 1.22)
Unknown	46	40.55	0	-	-